Fitness Trends Chronic Idiopathic Constipation (CIC) Treatment Ma

Chronic Idiopathic Constipation (CIC) Treatment Market -
Size, Share, Outlook and Opportunity Analysis, 2018-2026
Constipation is condition wherein the stool frequency reduces up to three times per week with
difficulty in stool passing. Chronic constipation is a highly common functional gastrointestinal
disorder that adversely affects patient’s life. Chronic idiopathic constipation is defined as the
presence of chronic symptoms of constipation with no well-defined underlying cause. The
symptoms of chronic idiopathic constipation includes infrequent bowel movements, hard stools,
straining during defecation, feeling of incomplete evacuation, abdominal discomfort, and
bloating sensation. Chronic idiopathic constipation is diagnosed by laboratory tests, endoscopy,
radiological tests, magnetic resonance imaging, and physiological testing. Currently, very few
approved treatment options are available for chronic idiopathic constipation, which is expected
to be a major factor restrain growth of the chronic idiopathic constipation treatment market.
However, this gives opportunity for the market player to come up with the novel treatment to
grab the foothold in growing chronic idiopathic constipation treatment market.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1791
Chronic Idiopathic Constipation (CIC) Treatment Market Dynamics
Increasing clinical trials and approval of drug candidates by pharmaceutical companies to fulfil
unmet medical needs of the chronic idiopathic constipation treatment is a key factor driving the
market growth over the forecast period. For instance, March 2018, Shire plc received new drug
application from U.S. FDA for its drug candidate, SHP555 (prucalopride) for the indication of
chronic idiopathic constipation in adults. Moreover, in 2015, SHP555 (prucalopride)received
approval from European Commission for the symptomatic treatment of chronic constipation in
adults with failure of laxative treatment. Furthermore, Renexxion is conducting phase 2 clinical
trial for Naronapride (ATI-7505) for the treatment of multiple gastrointestinal disorders, which
includes chronic idiopathic constipation. In 2017, FDA approved Ironwood and Allergan’s
Linzess (linaclotide) for the treatment of chronic idiopathic constipation. However, 50% of
patients with chronic constipation dissatisfied with their current treatment, mainly because of